Trials / Completed
CompletedNCT02945163
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
The Optimization of HAART for Chinese--a RCT Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir | Tenofovir Disoproxil Fumarate |
| DRUG | Lamivudine | Lamivudine |
| DRUG | Efavirenz | Efavirenz |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2019-06-05
- Completion
- 2019-08-31
- First posted
- 2016-10-26
- Last updated
- 2020-02-18
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02945163. Inclusion in this directory is not an endorsement.